Headache Disorders (Cluster & Migraine)
Psychedelics are being researched as potential treatments for headache disorders, including migraines and cluster headaches, which affect a significant portion of the global population. Early findings indicate that psychedelics may modulate pain perception and offer novel therapeutic pathways for those suffering from these debilitating conditions.
What is Headache Disorders (Cluster & Migraine)?
Headache disorders encompass a range of conditions characterized by ongoing or recurring headaches. The most common types include migraines, tension headaches, and cluster headaches, each varying in severity and symptomatology.
Migraine headaches are typically associated with pulsating pain, sensitivity to light and sound, and sometimes nausea. In contrast, tension headaches present as a dull, band-like pressure, while cluster headaches are characterised by intense, one-sided pain that occurs in cyclical patterns.
These disorders can severely impact quality of life and work productivity, affecting approximately 40% of the global population, particularly women who are more susceptible to migraines due to hormonal factors. They rank as leading causes of disability, especially for individuals aged 15 to 49.
Current Treatments
Standard treatments for headache disorders include acute medications such as analgesics (NSAIDs, acetaminophen), triptans for migraine relief, and preventive medications like beta-blockers, anticonvulsants, and antidepressants. Non-drug approaches, such as cognitive behavioural therapy, acupuncture, and lifestyle modifications, are also commonly employed.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for Headache Disorders (Cluster & Migraine).
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| LSD Evidence from early studies indicates LSD can stop headache attacks and extend remission, but further trials are needed for standardisation. | Large | Moderate | Inconsistent |
| Psilocybin Initial findings show psilocybin can significantly reduce migraine frequency; however, controlled studies are still ongoing. | Large | Moderate | Inconsistent |
| Ketamine Showing some initial effectiveness for acute cluster headaches, but more extensive research is required. | Medium | Low | Inconsistent |
LSD and Headache Disorders (Cluster & Migraine)
LSD appears to activate 5-HT2A serotonin receptors, playing a critical role in modulating pain signals and affecting the central and peripheral pain systems. This mechanism reduces pain perception and might contribute to anti-inflammatory effects, suggesting a dual approach to managing headaches.
Psilocybin and Headache Disorders (Cluster & Migraine)
Psilocybin's interaction with serotonin receptors also suggests significant potential in pain modulation. Research indicates it may alter pain perception pathways within the brain, potentially leading to significant reductions in headache frequency and intensity via non-hallucinogenic mechanisms.
Ketamine and Headache Disorders (Cluster & Migraine)
Unlike traditional psychedelics, ketamine operates primarily through NMDA receptor antagonism, showing promise in acute headache management. Initial studies indicate its potential in rapidly reducing pain intensity during cluster headaches, although its long-term efficacy requires further investigation.
Key Insights
- 1
Psychedelics, including LSD and psilocybin, have shown promise in aborting headache attacks and extending remission periods.
- 2
Activation of 5-HT2A receptors by psychedelics may help mitigate pain signals and reduce inflammation associated with headache disorders.
- 3
Initial studies indicate that a single dose of compounds like LSD may stop cluster headache cycles effectively, while psilocybin can significantly reduce migraine days.
- 4
Emerging therapies focus on non-hallucinogenic psychedelic derivatives, aiming for safer treatment options without psychoactive effects.
- 5
Research shows about 60% of LSD users report substantial reductions in the frequency of cluster headaches.
Industrial Landscape
Key players in psychedelic research for headache disorders include Ceruvia Lifesciences, which is developing the non-hallucinogenic derivative BOL-148, and Tactogen, focused on novel compounds like TACT908. Additionally, academic institutions and non-profits like Usona Institute are conducting rigorous studies on psychedelics, pushing for integration into mainstream medical practice.
Quick Indicators
\"Ongoing clinical evaluations are investigating Headache Disorders (Cluster & Migraine) as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with Headache Disorders (Cluster & Migraine).